Receive Excellent Coverage of Pharmaceutical Business, Compliance, Legal and Clinical Developments; Sign Up for a Complimentary Trial of Inside Health Policy

PRESS RELEASE
Contact: Steve Reilly
Phone: (703)-562-8992
Email: sreilly@iwpnews.com
Website: www.InsideHealthPolicy.com

WASHINGTON, DC USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- MARCH 5, 2026: Inside Health Policy delivers reporting you won't find elsewhere — forward-looking news essential for pharmaceutical and medical device manufacturers, PBMs, insurers, health care providers, hospitals' physician organizations and other health policy professionals, lawmakers and other government officials, lawyers, consultants and policy advisers.

Sign up for a free trial subscription to Inside Health Policy, the online news service on health care policy from the regulatory reporting experts at Inside Washington Publishers.

Here is a sample of the latest Inside Health Policy stories covering ACO and MA, two of the hottest issues in healthcare. You can read these stories, and many more, with your free trial:

• PhRMA, BIO Allege GLOBE, GUARD Models Illegal
  The top pharmaceutical and biotechnology lobbies allege the Trump administration's proposed Medicare models to tie drug inflation rebates to prices charged in other wealthy countries are illegal and should be scrapped, signaling they could sue if the models are finalized.
• Industry Urging Pfizer CEO To Fight MFN Codification Even as Deals Not Yet Finalized
  Some companies' "most favored nation" deals with the Trump administration to sell their drugs at lower prices in exchange for exemptions from tariffs are not yet finalized, Pfizer and Eli Lilly disclosed in their recent filings with the Securities and Exchange Commission. The disclosure that key details of the deals remain unsettled comes as Pfizer's CEO faces criticism from other drug makers for not taking a firmer stance against codifying the agreements, even as he draws headlines for his attacks on FDA leadership. Two industry lobbyists told Inside Health Policy major drugmakers are dissatisfied with Pfizer CEO Albert Bourla, who is also the chair of the brand-name pharmaceutical lobby's board, for not speaking out more forcefully against codifying the MFN deals, while other industry observers argue there is little reason to take a position on codification since the agreements were not finalized.
• Pharmacies To Face Low Cash Flow For MFP Drugs Until Fixes Emerge
  A bill introduced last year aiming to ensure long-term care (LTC) pharmacies can continue to supply and dispense Medicare Part D drugs despite lower prices resulting from the price negotiation program will need to be tweaked to ensure the intended relief is retroactive, according to Alan Rosenbloom, executive director of the Senior Care Pharmacy Coalition (SCPC).
• Bhattacharya Pushes NIH-CDC Integration, Targets Lower Costs For Gene Therapies
  Jay Bhattacharya, who is serving as both director of the National Institutes of Health and acting director of the Centers for Disease Control and Prevention, said the two agencies should be more integrated in an interview Friday (Feb. 27), arguing that closer alignment would speed the translation of federally funded research into large-scale public health deployment. He also said NIH is investing in technologies aimed at dramatically lowering the cost of gene therapies
• MAHA Memo Signals Strategic Retooling On Vaccine Messaging Ahead Of Midterms
  Republican strategists aligned with the Make America Healthy Again movement are recalibrating how they talk about vaccines as they look to bolster GOP prospects in the 2026 midterm elections, according to an internal MAHA Action memo obtained by Inside Health Policy. The memo mirrors the recent approach of senior administration health officials, who at public events have steered clear of discussing vaccines.

You can try Inside Health Policy for the next month with absolutely no obligation, your trial will simply expire at the end of 30 days. Your trial to Inside Health Policy includes online access to the newsletter you choose: Inside CMS, FDA Week, Health Exchange Alert, Inside Drug Pricing, or Inside Telehealth — and please call us if you want access to a second newsletter with your trial. Plus, if you choose to subscribe, we'll offer you 50% off for the first year of access. For more information about the 50% off, first-year savings, contact Steve Reilly at 703-562-8992, or e-mail him at sreilly@iwpnews.com.

FOR E-MAIL ADDRESS CHANGE, ADD OR DELETE REQUESTS:

For changes or additions, please email your request to: listmgrbm@HealthCareUpdateNewsService.com.

For removal of your e-mail address, please click the "SafeUnsubscribe" link located in the footer of this message below to automatically remove your address from the list.